Using liquid biopsies and breath samples to detect lung cancer mutations
Official title: A Prospective, Single Center Study to Test the Validity and Feasibility of Circulating Tumor DNA in Blood, Sputum and Alveolar Fluid, as Well as Exhaled Volatile Organic Compounds as Biomarkers in Non-Small Cell Lung Cancer
Run by St. Joseph's Healthcare Hamilton · NCT06707519 · Data updated 2026-11-12
This study is testing if using samples from blood, sputum, and breath can help find lung cancer mutations in patients with non-small cell lung cancer before and after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 210 (estimated) |
| Sponsor | St. Joseph's Healthcare Hamilton Academic / other |
| Locations | 1 site (Hamilton, Ontario) |
| Status | Recruiting |
| Started | February 1, 2023 |
| Main results expected | December 29, 2027 |
| Study ends | December 29, 2027 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT06707519 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old who are undergoing surgical resection with curative intent for NSCLC-adenocarcinoma.
✕Probably not a fit
Patients with non-curative surgical resections, metastatic disease, or other malignancies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the feasibility of recruiting participants and utilizing various biological samples, including sputum, bronchoalveolar lavage (BAL), and exhaled volatile organic compounds (VOC), alongside blood, to detect mutations in cell-free DNA in patients with non-small cell lung cancer (NSCLC). The study will follow patients undergoing surgical resection for NSCLC-adenocarcinoma, collecting samples at multiple time points before and after surgery, as well as during follow-up visits over a 24-month period. The goal is to evaluate the potential of these samples as novel biomarkers for monitoring disease recurrence and treatment response.
Why it matters
Potential benefit: If successful, this study could improve early detection of lung cancer recurrence and enhance monitoring of treatment responses.
How similar studies have gone: While the use of ctDNA in blood for cancer detection has shown promise, the validation of sputum and BAL samples for this purpose is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient must be at least 18 years of age * Patient must be able to provide consent * Patients undergoing surgical resection with curative intent for non-small cell lung cancer at St. Joseph's Healthcare Hamilton and Firestone Institute for Respiratory Health. Exclusion Criteria: * Resection done with non-curative intent or metastatic disease * other malignancies * Patients with previously treated malignancy less than 5 years prior to current resection (not including skin cancer).
Where it's running
-
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Layla Halwagi, BSc
- Email: Lhalwagi@stjosham.on.ca
- Phone: 905-522-1155
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.